Holen Sie sich die Stockscreener-App
109.47
2.56%
2.73
Schlusskurs vom Vortag:
$106.74
Offen:
$107.59
24-Stunden-Volumen:
606.81K
Relative Volume:
0.72
Marktkapitalisierung:
$6.29B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-36.98
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-2.71%
1M Leistung:
-0.69%
6M Leistung:
+19.26%
1J Leistung:
-25.22%
1-Tages-Spanne:
$106.75
$110.62
1-Wochen-Bereich:
$105.37
$115.19
52-Wochen-Spanne:
$73.16
$161.78
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
109.47 | 6.13B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
(GKOS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Does Glaukos Corporation meet Warren Buffett’s criteriaWeekly Trend Recap & Capital Efficient Trading Techniques - mfd.ru
Why Glaukos Corporation stock remains undervalued2025 Volume Leaders & Reliable Volume Spike Trade Alerts - mfd.ru
Globus Medical (GMED) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Stifel reiterates Buy rating on Glaukos stock with $160 price target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Glaukos stock with $160 price target - Investing.com Australia
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy? - Finviz
What is Glaukos Corporation’s market position2025 Major Catalysts & Weekly Momentum Picks - mfd.ru
Glaukos (GKOS) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Glaukos Corporation $GKOS Shares Sold by New York State Common Retirement Fund - MarketBeat
Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
C WorldWide Group Holding A S Acquires 45,000 Shares of Glaukos Corporation $GKOS - MarketBeat
How FDA Approval of Repeat iDose TR Use Will Impact Glaukos (GKOS) Investors - simplywall.st
Glaukos Corporation $GKOS Shares Sold by Brown Capital Management LLC - MarketBeat
Liquidity Mapping Around (GKOS) Price Events - Stock Traders Daily
Director Sells GKOS 15,000 Shares for $1.9 Million - AOL.com
11,479 Shares in Glaukos Corporation $GKOS Bought by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Glaukos (GKOS) Valuation After FDA Approval For Repeat iDose TR Use - simplywall.st
Glaukos Gains FDA Green Light For Repeat iDose TR Use - Yahoo Finance
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential - Yahoo Finance
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR - Yahoo Finance UK
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant - Yahoo Finance
Market Review: Will Glaukos Corporation outperform its industry peersJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Glaukos Achieves Regulatory and Commercial Milestones - AD HOC NEWS
Universal Beteiligungs und Servicegesellschaft mbH Sells 28,088 Shares of Glaukos Corporation $GKOS - MarketBeat
Glaukos rises as FDA greenlights labeling update for iDose TR - MSN
Is Neonode Inc forming bullish engulfing patternsQuarterly Portfolio Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Wells sees potential upside after Glaukos’ iDose repeat dosing label approved - Yahoo Finance
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Finviz
FDA approves Glaukos' iDose TR for repeat treatment labeling - Eyes On Eyecare
AustralianSuper Pty Ltd Increases Stock Position in Glaukos Corporation $GKOS - MarketBeat
Is Glaukos Corporation gaining market shareDip Buying & Free High Return Stock Watch Alerts - Mfd.ru
Glaukos Corporation (NYSE:GKOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Glaukos Receives FDA Approval of NDA Supplement for Re-Administration of iDose TR - VisionMonday.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR By Investing.com - Investing.com South Africa
Glaukos (NYSE:GKOS) Trading 6% Higher Following Analyst Upgrade - MarketBeat
Glaukos (NYSE:GKOS) Price Target Raised to $131.00 - MarketBeat
GKOS: BTIG Raises Price Target to $131 Amid Confidence in Glaukos | GKOS Stock News - GuruFocus
Glaukos stock rises on FDA approval for iDose TR re-administration - Investing.com
Glaukos stock rises on FDA approval for iDose TR re-administration By Investing.com - Investing.com South Africa
Glaukos (GKOS) Gains FDA Nod for iDose TR Re-administration Prot - GuruFocus
Glaukos (GKOS) Achieves FDA Approval for iDose Repeat Dosing Lab - GuruFocus
Glaukos wins FDA nod for iDose TR labeling update (GKOS:NYSE) - Seeking Alpha
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval By Investing.com - Investing.com Nigeria
Glaukos stock price target raised to $131 from $123 at BTIG on iDose approval - Investing.com Australia
FDA Approves Glaukos (GKOS) Repeat Administration Protocol for i - GuruFocus
Glaukos announces US FDA approval of NDA supplement allowing for re-administration of Idose® Tr - marketscreener.com
FDA approves repeat treatment protocol for Glaukos’ iDose TR - Investing.com
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):